This site is intended for healthcare professionals
FDA Hero Banner - Multi-coloured pills and tablets
FDA Drug information

Zolmitriptan

Read time: 1 mins
Marketing start date: 04 May 2024
...
 

Summary of product characteristics


Effective Time

20221031

Version

5

Spl Product Data Elements

Zolmitriptan Zolmitriptan ZOLMITRIPTAN ZOLMITRIPTAN ANHYDROUS CITRIC ACID ASPARTAME SILICON DIOXIDE CROSPOVIDONE (15 MPA.S AT 5%) GELATIN MAGNESIUM STEARATE MANNITOL CELLULOSE, MICROCRYSTALLINE ORANGE POLACRILIN POTASSIUM SODIUM STEARYL FUMARATE WHITE/MOTTLED WHITE TO CREAM WHITE ORANGE ROUND 715 Zolmitriptan Zolmitriptan ZOLMITRIPTAN ZOLMITRIPTAN ANHYDROUS CITRIC ACID ASPARTAME SILICON DIOXIDE CROSPOVIDONE (15 MPA.S AT 5%) GELATIN MAGNESIUM STEARATE MANNITOL CELLULOSE, MICROCRYSTALLINE ORANGE POLACRILIN POTASSIUM SODIUM STEARYL FUMARATE WHITE/MOTTLED WHITE TO CREAM WHITE ORANGE ROUND 717

Application Number

ANDA202890

Brand Name

Zolmitriptan

Generic Name

Zolmitriptan

Product Ndc

65841-768

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

NDC 65841-767-10 in bottle of 1000 Tablets Zolmitriptan Orally Disintegrating Tablets, 2.5 mg Rx only 1000 Tablets Zolmitriptan OD Tablets, 2.5 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.